Malignant pheochromocytomas and paragangliomas affect a very small percentage of the
general population. A substantial number of these patients have a hereditary predisposition …

Pheochromocytomas and paragangliomas continue to be defined by significant morbidity
and mortality despite their several recent advances in diagnosis, localization, and …

There is currently no completely effective therapy available for metastatic
pheochromocytomas or paragangliomas. Increasing understanding of the germline and …

Abstract Learning Objectives Discuss the advances in molecular genetics which have
uncovered new hereditary and germline mutations contributing to the development of …

Pheochromocytomas (PHEOs) are rare neuroendocrine tumors that arise from the
chromaffin cells of the adrenal glands. Paragangliomas (PGLs), the extra-adrenal …

Background Pheochromocytomas and paragangliomas are intra-and extra-adrenal
neoplasms that are rarely malignant. The treatment of those that are malignant has …

Pheochromocytomas (PCC) and paragangliomas (PGL) are rare neuroendocrine tumors
that arise in the adrenal medulla and in extra-adrenal locations, such as the head, neck …

Pheochromocytoma and paraganglioma (PCC/PGL) are rare tumors that originate from
adrenal or extra-adrenal chromaffin cells. A significant clinical manifestation of PCC/PGL is …

Pheochromocytomas and paragangliomas are the most heritable endocrine tumors. In
addition to the inherited mutation other driver mutations have also been identified in tumor …

Patients having malignant pheochromocytomas and paragangliomas traditionally have
been treated with systemic chemotherapy and 131 I-meta-iodobenzylguanidine. However …